Key Points
- Harold Bernstein, Maze's Chief Medical Officer, sold 45,000 shares on Dec. 29 at an average of $40.56, generating about $1.83 million according to the SEC filing.
- Other insiders also executed large sales (Atul Dandekar ~72,400 shares, Amy Bachrodt 15,000 shares), which may weigh on sentiment even as analysts maintain a consensus "Buy" rating and have raised price targets (consensus target ~$43.38; HC Wainwright $60; Wells Fargo $55).
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $40.08, for a total value of $200,400.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares in the company, valued at $519,637.20. This represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amy Bachrodt also recently made the following trade(s):
- On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00.
Maze Therapeutics Stock Up 3.4%
Maze Therapeutics stock opened at $41.43 on Thursday. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $43.29. The firm has a market capitalization of $1.99 billion and a price-to-earnings ratio of -1.98. The firm has a 50-day moving average price of $36.58 and a two-hundred day moving average price of $24.58.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.08.
Maze Therapeutics News Summary
Here are the key news stories impacting Maze Therapeutics this week:
-
Positive Sentiment: Analysts raised price targets and the consensus remains a "Buy" (consensus target ~ $43.38), supporting upward momentum from renewed sell-side optimism. Read More.
-
Positive Sentiment: Several institutional investors established new stakes in recent quarters (e.g., Charles Schwab Investment Management, Invesco, Nuveen), signaling institutional interest that can support the share price. Read More.
-
Neutral Sentiment: Recent quarterly results (11/6) showed an EPS beat (reported -$0.66 vs. consensus -$0.74), which is supportive but still reflects an unprofitable, clinical-stage profile. Read More.
-
Neutral Sentiment: A de minimis insider sale of 100 shares by Atul Dandekar (Dec. 30) is immaterial on its own. Read More.
-
Negative Sentiment: Chief Medical Officer Harold Bernstein sold 45,000 shares at an average $40.56 (≈ $1.83M). Large C‑suite sales can raise concern about insider sentiment or trigger short-term selling pressure. Read More.
-
Negative Sentiment: Insider Atul Dandekar sold 72,400 shares at ~$40.56 (~$2.94M), cutting his ownership by ~87.3% (now 10,503 shares). The size and percentage reduction make this the most market‑negative item and could weigh on sentiment. Read More.
-
Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (10,000 at $40.58; 5,000 at $40.08; ≈ $606K), materially reducing her stake — another signal that may damp investor confidence. Read More.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. lifted its position in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after acquiring an additional 438,274 shares during the last quarter. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the first quarter worth $45,362,000. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company's stock worth $34,615,000 after purchasing an additional 915,342 shares during the period. Woodline Partners LP lifted its holdings in shares of Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company's stock valued at $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company's stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, December 13th. HC Wainwright upped their price target on shares of Maze Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, December 3rd. Guggenheim reiterated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. BTIG Research boosted their target price on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Finally, Lifesci Capital raised Maze Therapeutics to a "strong-buy" rating in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $43.38.
Read Our Latest Analysis on Maze Therapeutics
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
